Results 21 to 30 of about 70,330 (230)

Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colorectal Cancer

Cellular Physiology and Biochemistry, 2017
Background/Aims: Cetuximab is a chimeric IgG1 monoclonal antibody which targets the extracellular domain of epidermal growth factor receptor. This antibody is widely used for colorectal cancer (CRC) treatment but its influence on the immune system is ...
Lin Wang, Yingfeng Wei, Weijia Fang, Chong Lu, Jianing Chen, Guangying Cui, Hongyan Diao   +6 more
doaj   +1 more source

Platycodin D sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the PI3K/Akt signaling pathway

Frontiers in Oncology, 2022
Cetuximab is a monoclonal antibody against epidermal growth factor receptor that blocks downstream signaling pathways of receptor tyrosine kinases, including Ras/Raf/MAPK and PI3K/Akt, thereby inhibiting tumor cell proliferation and inducing cancer cell ...
Yanfei Liu, Yanfei Liu, Shifeng Tian, Ben Yi, Ben Yi, Zhiqiang Feng, Zhiqiang Feng, Tianhao Chu, Tianhao Chu, Jun Liu, Chunze Zhang, Shiwu Zhang, Yijia Wang   +12 more
doaj   +1 more source

Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma [PDF]

, 2018
Rationale:Small bowel adenocarcinoma (SBA) is an uncommon gastrointestinal cancer, thus limited data about treatment for advanced disease are available.
Anselmi, Elisabetta, Falcone, Rosa, Filetti, Marco, Marchetti, Paolo, Roberto, Michela   +4 more
core   +1 more source

Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies

Pharmacology Research & Perspectives, 2019
The pharmacokinetics and potential drug–drug interactions between cetuximab and cisplatin or carboplatin from two studies (JXBA and JXBB) were evaluated.
Raymond P. Perez, Eric Chen, J. Thaddeus Beck, Keisuke Shirai, David Neil Hayes, Tong Shen, John R. Baldwin, Katherine B. Bryant, Shuang He, Steve Chin   +9 more
doaj   +1 more source

Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC). [PDF]

, 2018
The landscape of head and neck squamous cell carcinoma (HNSCC) has been changing rapidly due to growing proportion of HPV-related disease and development of new therapeutic agents.
Jung, Kyungsuk, Kang, Hyunseok, Mehra, Ranee   +2 more
core   +2 more sources

Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC) [PDF]

, 2013
Management of metastatic colorectal cancer requires a multimodal approach and must be performed by an experienced, multidisciplinary expert team. The optimal choice of the individual treatment modality, according to disease localization and extent, tumor
BASSO, ENRICO, CARUSO, DAVIDE, EVANGELISTA, SALVATORE, Foteini Vakiarou, G. Rinaldi, L. Bianchi, Lo Russo, Giuseppe, PAPA, ANSELMO, Perrone-congedi, Francesca, PRETE, ALESSANDRA ANNA, ROSSI, Luigi, SPINELLI, GIAN PAOLO, Stati, Valeria, TOMAO, SILVERIO, VERRICO, MONICA, ZORATTO, federica   +15 more
core   +1 more source

Laryngeal Preservation Strategies in Locally Advanced Laryngeal and Hypopharyngeal Cancers. [PDF]

, 2019
For long, the treatment of locoregionally advanced laryngeal and hypopharyngeal squamous cell cancers (SCC) consisted of either total laryngectomy (TL) or definitive radiotherapy (RT).
Argiris, Athanassios, Lefebvre, Jean Louis   +1 more
core   +2 more sources

Long noncoding RNA and mRNA profiling in cetuximab‐resistant colorectal cancer cells by RNA sequencing analysis

Cancer Medicine, 2019
To gain an insight into the molecular mechanisms of cetuximab resistance in colorectal cancer, we generated a cetuximab‐resistant cell line (H508/CR) and performed RNA sequencing to identify the differential expression patterns of noncoding RNAs (ncRNAs)
Changwen Jing, Rong Ma, Haixia Cao, Zhuo Wang, Siwen Liu, Dan Chen, Yang Wu, Junying Zhang, Jianzhong Wu   +8 more
doaj   +1 more source

A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells

Toxins, 2023
Cetuximab is a monoclonal antibody blocking the epidermal growth factor receptor (EGFR) in metastatic colorectal cancer (mCRC). However, cetuximab treatment has no clinical benefits in patients affected by mCRC with KRAS mutation or in the presence of ...
Nicola Landi, Vincenza Ciaramella, Sara Ragucci, Angela Chambery, Fortunato Ciardiello, Paolo V. Pedone, Teresa Troiani, Antimo Di Maro   +7 more
doaj   +1 more source

Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. [PDF]

, 2013
BackgroundPreclinical data indicate EGFR signals through both kinase-dependent and independent pathways and that combining a small-molecule EGFR inhibitor, EGFR antibody, and/or anti-angiogenic agent is synergistic in animal models.MethodsWe conducted a ...
Bastida, Christel, Falchook, Gerald S, Fu, Siqing, Hong, David S, Jiang, Yunfang, Kurzrock, Razelle, Morgan-Linnell, Sonia K, Naing, Aung, Piha-Paul, Sarina A, Tsimberidou, Apostolia M, Wheler, Jennifer J, Zinner, Ralph   +11 more
core   +2 more sources